Bulletin
Investor Alert

Annovis Bio Inc.

NYS: ANVS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Feb 3, 2023, 7:22 p.m.

/zigman2/quotes/216213707/composite

$

19.44

Change

+0.10 +0.52%

Volume

Volume 39

Quotes are delayed by 20 min

/zigman2/quotes/216213707/composite

Previous close

$ 19.33

$ 19.34

Change

+0.01 +0.05%

Day low

Day high

$18.50

$20.99

Open

52 week low

52 week high

$8.39

$23.91

Open

Claudine E. Bruck

Founder of Prolifagen LLC, Claudine E. Bruck presently holds the position of Chairman for Prolifagen LLC and Chief Scientific Officer of SapVax LLC. Dr. Bruck is also on the board of Annovis Bio, Inc.

She previously was Head-Cancer Vaccine Program at GlaxoSmithKline LLC, Course Director at the University of Pennsylvania and Assistant Professor at Tufts University School of Medicine.

Claudine E. Bruck received a doctorate from Vrije Universiteit Brussel and a graduate degree from Harvard Medical School.

Transactions

Date Shares Transaction Value
10/11/2021 181   Acquisition at $27.66 per share. 5,006
01/31/2020 1,117   Derivative/Non-derivative trans. at $4.8 per share. 5,361
01/31/2020 3,969   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 800   Acquisition at $6 per share. 4,800

Officers and Executives

Dr. Maria-Luisa Maccecchini
President, Chief Executive Officer & Director
Mr. Henry Hagopian
Dr. Cheng Fang
Senior Vice President-Research & Development
Ms. Eve M. Damiano
Senior Vice President-Regulatory Operations
Mr. Michael B. Hoffman
Chairman
Mr. Reid S. McCarthy
Independent Director
Dr. Claudine E. Bruck
Independent Director
Mr. Mark White
Independent Director
Link to MarketWatch's Slice.